Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17


Trends in Incidence and Stage at Diagnosis of Colorectal Cancer in Adults Aged 40 Through 49 Years, 1975-2015.

Meester RGS, Mannalithara A, Lansdorp-Vogelaar I, Ladabaum U.

JAMA. 2019 May 21;321(19):1933-1934. doi: 10.1001/jama.2019.3076. No abstract available.


Cost-Effectiveness of Colonoscopy-Based Colorectal Cancer Screening in Childhood Cancer Survivors.

Gini A, Meester RGS, Keshavarz H, Oeffinger KC, Ahmed S, Hodgson DC, Lansdorp-Vogelaar I.

J Natl Cancer Inst. 2019 Apr 13. pii: djz060. doi: 10.1093/jnci/djz060. [Epub ahead of print]


Cost-effectiveness and National Effects of Initiating Colorectal Cancer Screening for Average-risk Persons at Age 45 Years Instead of 50 Years.

Ladabaum U, Mannalithara A, Meester RGS, Gupta S, Schoen RE.

Gastroenterology. 2019 Mar 28. pii: S0016-5085(19)33578-4. doi: 10.1053/j.gastro.2019.03.023. [Epub ahead of print]


Optimizing colorectal cancer screening by race and sex: Microsimulation analysis II to inform the American Cancer Society colorectal cancer screening guideline.

Meester RGS, Peterse EFP, Knudsen AB, de Weerdt AC, Chen JC, Lietz AP, Dwyer A, Ahnen DJ, Siegel RL, Smith RA, Zauber AG, Lansdorp-Vogelaar I.

Cancer. 2018 Jul 15;124(14):2974-2985. doi: 10.1002/cncr.31542. Epub 2018 May 30.


The impact of the rising colorectal cancer incidence in young adults on the optimal age to start screening: Microsimulation analysis I to inform the American Cancer Society colorectal cancer screening guideline.

Peterse EFP, Meester RGS, Siegel RL, Chen JC, Dwyer A, Ahnen DJ, Smith RA, Zauber AG, Lansdorp-Vogelaar I.

Cancer. 2018 Jul 15;124(14):2964-2973. doi: 10.1002/cncr.31543. Epub 2018 May 30.


Value Of Waiving Coinsurance For Colorectal Cancer Screening In Medicare Beneficiaries.

Peterse EFP, Meester RGS, Gini A, Doubeni CA, Anderson DS, Berger FG, Zauber AG, Lansdorp-Vogelaar I.

Health Aff (Millwood). 2017 Dec;36(12):2151-2159. doi: 10.1377/hlthaff.2017.0228.


Effect of Time to Diagnostic Testing for Breast, Cervical, and Colorectal Cancer Screening Abnormalities on Screening Efficacy: A Modeling Study.

Rutter CM, Kim JJ, Meester RGS, Sprague BL, Burger EA, Zauber AG, Ergun MA, Campos NG, Doubeni CA, Trentham-Dietz A, Sy S, Alagoz O, Stout N, Lansdorp-Vogelaar I, Corley DA, Tosteson ANA.

Cancer Epidemiol Biomarkers Prev. 2018 Feb;27(2):158-164. doi: 10.1158/1055-9965.EPI-17-0378. Epub 2017 Nov 17.


Impact of adenoma detection on the benefit of faecal testing vs. colonoscopy for colorectal cancer.

Meester RGS, Doubeni CA, Zauber AG, van Ballegooijen M, Corley DA, Lansdorp-Vogelaar I.

Int J Cancer. 2017 Dec 1;141(11):2359-2367. doi: 10.1002/ijc.30933. Epub 2017 Aug 31.


Colorectal cancer statistics, 2017.

Siegel RL, Miller KD, Fedewa SA, Ahnen DJ, Meester RGS, Barzi A, Jemal A.

CA Cancer J Clin. 2017 May 6;67(3):177-193. doi: 10.3322/caac.21395. Epub 2017 Mar 1.


Cost effectiveness of surveillance for GI cancers.

Omidvari AH, Meester RG, Lansdorp-Vogelaar I.

Best Pract Res Clin Gastroenterol. 2016 Dec;30(6):879-891. doi: 10.1016/j.bpg.2016.09.001. Epub 2016 Sep 12. Review.


Consequences of Increasing Time to Colonoscopy Examination After Positive Result From Fecal Colorectal Cancer Screening Test.

Meester RG, Zauber AG, Doubeni CA, Jensen CD, Quinn VP, Helfand M, Dominitz JA, Levin TR, Corley DA, Lansdorp-Vogelaar I.

Clin Gastroenterol Hepatol. 2016 Oct;14(10):1445-1451.e8. doi: 10.1016/j.cgh.2016.05.017. Epub 2016 May 19. Erratum in: Clin Gastroenterol Hepatol. 2018 May;16(5):787. Clin Gastroenterol Hepatol. 2018 Aug;16(8):1365.


Colorectal cancer screening: Estimated future colonoscopy need and current volume and capacity.

Joseph DA, Meester RG, Zauber AG, Manninen DL, Winges L, Dong FB, Peaker B, van Ballegooijen M.

Cancer. 2016 Aug 15;122(16):2479-86. doi: 10.1002/cncr.30070. Epub 2016 May 20. Erratum in: Cancer. 2017 Oct 1;123(19):3857.


Personalizing colonoscopy screening for elderly individuals based on screening history, cancer risk, and comorbidity status could increase cost effectiveness.

van Hees F, Saini SD, Lansdorp-Vogelaar I, Vijan S, Meester RG, de Koning HJ, Zauber AG, van Ballegooijen M.

Gastroenterology. 2015 Nov;149(6):1425-37. doi: 10.1053/j.gastro.2015.07.042. Epub 2015 Aug 4.


Variation in Adenoma Detection Rate and the Lifetime Benefits and Cost of Colorectal Cancer Screening: A Microsimulation Model.

Meester RG, Doubeni CA, Lansdorp-Vogelaar I, Jensen CD, van der Meulen MP, Levin TR, Quinn VP, Schottinger JE, Zauber AG, Corley DA, van Ballegooijen M.

JAMA. 2015 Jun 16;313(23):2349-58. doi: 10.1001/jama.2015.6251.


Public health impact of achieving 80% colorectal cancer screening rates in the United States by 2018.

Meester RG, Doubeni CA, Zauber AG, Goede SL, Levin TR, Corley DA, Jemal A, Lansdorp-Vogelaar I.

Cancer. 2015 Jul 1;121(13):2281-5. doi: 10.1002/cncr.29336. Epub 2015 Mar 12.


Colorectal cancer deaths attributable to nonuse of screening in the United States.

Meester RG, Doubeni CA, Lansdorp-Vogelaar I, Goede SL, Levin TR, Quinn VP, Ballegooijen Mv, Corley DA, Zauber AG.

Ann Epidemiol. 2015 Mar;25(3):208-213.e1. doi: 10.1016/j.annepidem.2014.11.011. Epub 2014 Dec 5.


Should colorectal cancer screening be considered in elderly persons without previous screening? A cost-effectiveness analysis.

van Hees F, Habbema JD, Meester RG, Lansdorp-Vogelaar I, van Ballegooijen M, Zauber AG.

Ann Intern Med. 2014 Jun 3;160(11):750-9. doi: 10.7326/M13-2263.

Supplemental Content

Loading ...
Support Center